ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
41.03
0.49%
US Tech 100
21,420.00
1.36%
S&P 500
6,115.07
1.04%
US Dollar vs CAD
1.41914
-0.01%
Bitcoin
96,727.80
0.11%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. ZyVersa Therapeutics Inc (ZVSA)

  7. ZyVersa Therapeutics Inc (ZVSA) News

ZVSA

ZyVersa Therapeutics (ZVSA)

ZyVersa Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ZVSA
DateTimeSourceHeadlineSymbolCompany
01/24/20253:05PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ZVSAZyVersa Therapeutics Inc
01/17/20253:05PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ZVSAZyVersa Therapeutics Inc
12/30/20247:30AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ZVSAZyVersa Therapeutics Inc
12/26/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ZVSAZyVersa Therapeutics Inc
12/20/20244:04PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ZVSAZyVersa Therapeutics Inc
12/20/20243:15PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ZVSAZyVersa Therapeutics Inc
12/18/20246:55AMGlobeNewswire Inc.ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San FranciscoNASDAQ:ZVSAZyVersa Therapeutics Inc
11/20/20246:55AMGlobeNewswire Inc.ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical TrialNASDAQ:ZVSAZyVersa Therapeutics Inc
11/15/20247:35AMGlobeNewswire Inc.Life Sciences Investor Forum: Presentations Now Available for Online ViewingNASDAQ:ZVSAZyVersa Therapeutics Inc
11/14/20247:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVSAZyVersa Therapeutics Inc
11/14/20247:10AMGlobeNewswire Inc.ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business UpdateNASDAQ:ZVSAZyVersa Therapeutics Inc
11/14/20247:00AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ZVSAZyVersa Therapeutics Inc
11/06/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVSAZyVersa Therapeutics Inc
11/05/20246:00AMGlobeNewswire Inc.ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 DiabetesNASDAQ:ZVSAZyVersa Therapeutics Inc
10/30/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVSAZyVersa Therapeutics Inc
10/29/20246:57AMGlobeNewswire Inc.ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss DrugsNASDAQ:ZVSAZyVersa Therapeutics Inc
10/22/20246:57AMGlobeNewswire Inc.ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative DiseasesNASDAQ:ZVSAZyVersa Therapeutics Inc
10/17/20246:50AMGlobeNewswire Inc.ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine MonthsNASDAQ:ZVSAZyVersa Therapeutics Inc
10/15/20246:50AMGlobeNewswire Inc.ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome InhibitorsNASDAQ:ZVSAZyVersa Therapeutics Inc
10/07/20246:55AMGlobeNewswire Inc.ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic ComplicationsNASDAQ:ZVSAZyVersa Therapeutics Inc
09/16/20244:30PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ZVSAZyVersa Therapeutics Inc
09/16/20244:29PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVSAZyVersa Therapeutics Inc
09/10/20246:25AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ZVSAZyVersa Therapeutics Inc
09/10/20246:22AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ZVSAZyVersa Therapeutics Inc
09/09/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ZVSAZyVersa Therapeutics Inc
09/09/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ZVSAZyVersa Therapeutics Inc
09/09/20243:35PMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ZVSAZyVersa Therapeutics Inc
09/09/20243:32PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ZVSAZyVersa Therapeutics Inc
09/09/20243:30PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ZVSAZyVersa Therapeutics Inc
09/03/20244:29PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ZVSAZyVersa Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ZVSA

Your Recent History

TSXV
CLAS.WT.A
Claritas Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads